Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGWP.L Regulatory News (GWP)

  • There is currently no data for GWP

Blocklisting Interim Review

17 Feb 2011 17:46

RNS Number : 4529B
GW Pharmaceuticals PLC
17 February 2011
Β 

Β 

Β 

BLOCKLISTING INTERIM REVIEW

Β 

1. NAME OF COMPANY:

Β 

GW PHARMACEUTICALS PLC

Β 

2. NAME OF SCHEME:

Β 

GW PHARMACEUTICALS APPROVED COMPANY SHARE OPTION SCHEME

Β 

3. PERIOD OF RETURN:

Β 

FROM: 1 NOVEMBER 2009 TO: 17 FEBRUARY 2011

Β 

4. NUMBER AND CLASS OF SHARES(S) (AMOUNT OF STOCK/DEBT SECURITY) NOT ISSUED UNDER SCHEME AT END OF THE LAST PERIOD:

Β 

145,400 ORDINARY SHARES OF 0.1P EACH

Β 

5. NUMBER OF SHARES ISSUED/ALLOTTED UNDER SCHEME DURING PERIOD:

Β 

67,500 ORDINARY SHARES OF 0.1P EACH

Β 

6. BALANCE UNDER SCHEME NOT YET ISSUED/ALLOTTED AT END OF PERIOD:

Β 

77,900 ORDINARY SHARES OF 0.1P EACH

Β 

7. NUMBER AND CLASS OF SHARE(S) (AMOUNT OF STOCK/DEBT SECURITIES) ORIGINALLY LISTED AND THE DATE OF ADMISSION:

Β 

507,146 ORDINARY SHARES OF 0.1P EACH ON 7 OCTOBER 2003

Β 

PLEASE CONFIRM TOTAL NUMBER OF SHARES IN ISSUE AT THE END OF THE PERIOD IN ORDER FOR US TO UPDATE OUR RECORDS.

Β 

131,549,592 ORDINARY SHARES OF 0.1P EACH

Β 

Β 

Β 

BLOCKLISTING INTERIM REVIEW

Β 

1. NAME OF COMPANY:

Β 

GW PHARMACEUTICALS PLC

Β 

2. NAME OF SCHEME:

Β 

GW PHARMACEUTICALS APPROVED SHARE OPTION SCHEME 2001

Β 

3. PERIOD OF RETURN:

Β 

FROM: 01 NOVEMBER 2009 TO: 17 FEBRUARY 2011

Β 

4. NUMBER AND CLASS OF SHARES(S) (AMOUNT OF STOCK/DEBT SECURITY) NOT ISSUED UNDER SCHEME AT END OF THE LAST PERIOD:

Β 

384,958 ORDINARY SHARES OF 0.1P EACH

Β 

5. NUMBER OF SHARES ISSUED/ALLOTTED UNDER SCHEME DURING PERIOD:

Β 

102,000 ORDINARY SHARES OF 0.1P EACH

Β 

6. BALANCE UNDER SCHEME NOT YET ISSUED/ALLOTTED AT END OF PERIOD:

Β 

282,958 ORDINARY SHARES OF 0.1P EACH

Β 

7. NUMBER AND CLASS OF SHARE(S) (AMOUNT OF STOCK/DEBT SECURITIES) ORIGINALLY LISTED AND THE DATE OF ADMISSION:

Β 

516,558 ORDINARY SHARES OF 0.1P EACH ON 21 JULY 2004

Β 

PLEASE CONFIRM TOTAL NUMBER OF SHARES IN ISSUE AT THE END OF THE PERIOD IN ORDER FOR US TO UPDATE OUR RECORDS.

Β 

131,549,592 ORDINARY SHARES OF 0.1P EACH

Β 

Β 

BLOCKLISTING INTERIM REVIEW

Β 

1. NAME OF COMPANY:

Β 

GW PHARMACEUTICALS PLC

Β 

2. NAME OF SCHEME:

Β 

GW PHARMACEUTICALS UNAPPROVED SHARE OPTION SCHEME 2001

Β 

3. PERIOD OF RETURN:

Β 

FROM: 01 NOVEMBER 2009 TO: 17 FEBRUARY 2011

Β 

4. NUMBER AND CLASS OF SHARES(S) (AMOUNT OF STOCK/DEBT SECURITY) NOT ISSUED UNDER SCHEME AT END OF THE LAST PERIOD:

Β 

1,276,492 ORDINARY SHARES OF 0.1P EACH

Β 

5. NUMBER OF SHARES ISSUED/ALLOTTED UNDER SCHEME DURING PERIOD:

Β 

657,833 ORDINARY SHARES OF 0.1P EACH

Β 

6. BALANCE UNDER SCHEME NOT YET ISSUED/ALLOTTED AT END OF PERIOD:

Β 

618,659 ORDINARY SHARES OF 0.1P EACH

Β 

7. NUMBER AND CLASS OF SHARE(S) (AMOUNT OF STOCK/DEBT SECURITIES) ORIGINALLY LISTED AND THE DATE OF ADMISSION:

Β 

1,279,192 ORDINARY SHARES OF 0.1P EACH ON 21 JULY 2004

Β 

PLEASE CONFIRM TOTAL NUMBER OF SHARES IN ISSUE AT THE END OF THE PERIOD IN ORDER FOR US TO UPDATE OUR RECORDS.

Β 

131,549,592 ORDINARY SHARES OF 0.1P EACH

Β 

Β 

BLOCKLISTING INTERIM REVIEW

Β 

1. NAME OF COMPANY:

Β 

GW PHARMACEUTICALS PLC

Β 

2. NAME OF SCHEME:

Β 

GW PHARMACEUTICALS EXECUTIVE SHARE OPTION SCHEME

Β 

3. PERIOD OF RETURN:

Β 

FROM: 1 NOVEMBER 2009 TO: 17 FEBRUARY 2011

Β 

4. NUMBER AND CLASS OF SHARES(S) (AMOUNT OF STOCK/DEBT SECURITY) NOT ISSUED UNDER SCHEME AT END OF THE LAST PERIOD:

Β 

212,612 ORDINARY SHARES OF 0.1P EACH

Β 

5. NUMBER OF SHARES ISSUED/ALLOTTED UNDER SCHEME DURING PERIOD:

Β 

212,612 ORDINARY SHARES OF 0.1P EACH

Β 

6. BALANCE UNDER SCHEME NOT YET ISSUED/ALLOTTED AT END OF PERIOD:

Β 

NIL ORDINARY SHARES OF 0.1P EACH.

Β 

7. NUMBER AND CLASS OF SHARE(S) (AMOUNT OF STOCK/DEBT SECURITIES) ORIGINALLY LISTED AND THE DATE OF ADMISSION:

Β 

1,388,375 ORDINARY SHARES OF 0.1P EACH ON 7 OCTOBER 2003

300,000 ORDINARY SHARES OF 0.1P EACH ON 23 APRIL 2008

400,000 ORDINARY SHARES OF 0.1P EACH ON 18 JANUARY 2010

Β 

PLEASE CONFIRM TOTAL NUMBER OF SHARES IN ISSUE AT THE END OF THE PERIOD IN ORDER FOR US TO UPDATE OUR RECORDS.

Β 

131,549,592 ORDINARY SHARES OF 0.1P EACH

Β 

Β 

Β 

For further information, please contact:

Β 

Adam George, Company Secretary, GW Pharmaceuticals plc

Β 

Telephone: +44 (0)1980 557000

Β 

James Steel/Vijay Barathan, Nominated Adviser, Peel Hunt LLP

Β 

Telephone: +44 (0)20 7418 8900

Β 

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
BLRDDLFFFLFZBBL
Date   Source Headline
10th May 20134:24 pmRNSHolding(s) in Company
9th May 20133:40 pmRNSTotal Voting Rights
8th May 20138:00 amRNSClosing of Initial Public Offering on Nasdaq
7th May 20137:00 amRNSSativex Commercialization Approval in Italy
1st May 20135:47 pmRNSPricing of U.S. Initial Public Offering
22nd Apr 20137:00 amRNSUS Patent Allowance for SATIVEX Formulation Spray
18th Apr 20132:23 pmRNSAmendment to Registration Statement for NASDAQ
12th Apr 201310:31 amRNSResults of General Meeting
10th Apr 20137:00 amRNSSativex moved to Schedule 4 of UK Drugs Act
3rd Apr 20137:00 amRNSNew US Patent Allowance for Delivery of SATIVEX
22nd Mar 20132:35 pmRNSPosting of Shareholder Circular
19th Mar 20132:46 pmRNSAppoints Stephen Schultz VP of Investor Relations
19th Mar 20131:10 pmRNSUpdate on Sativex in Germany
19th Mar 20131:01 pmRNSFiling for listing on NASDAQ
19th Feb 20133:16 pmRNSDirectorate Change
19th Feb 20139:30 amRNSBlocklisting Interim Review
4th Dec 201210:04 amRNSDirector/PDMR Shareholding
30th Nov 20122:54 pmRNSDirector/PDMR Shareholding
30th Nov 20122:50 pmRNSDirector/PDMR Shareholding
28th Nov 20127:00 amRNSPreliminary Results
28th Nov 20127:00 amRNSPhIIa Study Identifies New Anti-Diabetic Treatment
22nd Nov 201211:31 amRNSNotice of Results
12th Nov 20127:00 amRNSGW to Present at Lazard Healthcare Conference
12th Oct 20127:00 amRNSPositive German Sativex Data Presented at ECTRIMS
1st Oct 20127:00 amRNSAppointment of Chief Operating Officer
13th Sep 20127:00 amRNSPublication of New Epilepsy Data
20th Aug 201212:14 pmRNSDirector/PDMR Shareholding
17th Aug 20124:04 pmRNSBlocklisting Interim Review
22nd Jun 20127:00 amRNSGerman GBA establishes positive benefit of Sativex
13th Jun 201210:19 amRNSDirector/PDMR Shareholding
6th Jun 20124:03 pmRNSDirector/PDMR Shareholding
23rd May 20123:56 pmRNSDirector/PDMR Shareholding
22nd May 20127:00 amRNSThird Cancer Pain Trial Commences
22nd May 20127:00 amRNSInterim Results
8th May 20127:00 amRNSSuccessful completion of MRP for Sativex
26th Apr 201211:00 amRNSNotice of Results
23rd Apr 20127:00 amRNSSativex phase IIb pain trial results publication
16th Apr 20127:00 amRNSAlmirall Milestone
5th Apr 20127:00 amRNSBoard Changes
2nd Apr 20122:31 pmRNSDirector/PDMR Shareholding
30th Mar 20121:57 pmRNSDirector/PDMR Shareholding
15th Mar 20127:00 amRNSGW and Almirall Strengthen Strategic Collaboration
8th Mar 20127:00 amRNSAppointment of Professor Vincenzo Di Marzo
17th Feb 20127:00 amRNSBlocklisting Interim Review
7th Feb 20127:00 amRNSSATIVEX® Regulatory Approval Received in Austria
25th Jan 20121:46 pmRNSResult of AGM
11th Jan 201211:43 amRNSHolding(s) in Company
11th Jan 201211:42 amRNSHolding(s) in Company
28th Dec 201110:39 amRNSDirector/PDMR Shareholding
22nd Dec 20117:00 amRNSSativex Approval in Sweden

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.